Fmr LLC Amylyx Pharmaceuticals, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Fmr LLC holds 56,379 shares of AMLX stock, worth $317,977. This represents 0.0% of its overall portfolio holdings.

Number of Shares

56,379

Previous 19,390 190.76%

Holding current value

$317,977

Previous $55,000 94.55%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.62 - $2.71 $59,922 - $100,240	36,989 Added 190.76%	56,379 $107,000
Q1 2024 May 13, 2024	SELL	$2.71 - $19.57 $3.84 Million - $27.7 Million	-1,416,761 Reduced 98.65%	19,390 $55,000
Q4 2023 Feb 13, 2024	BUY	$12.07 - $18.46 $12 Million - $18.4 Million	997,465 Added 227.38%	1,436,151 $21.1 Million
Q3 2023 Nov 13, 2023	SELL	$18.08 - $23.45 $186,151 - $241,441	-10,296 Reduced 2.29%	438,686 $8.03 Million
Q2 2023 Aug 11, 2023	BUY	$20.98 - $31.42 $9.27 Million - $13.9 Million	441,752 Added 6109.99%	448,982 $9.68 Million
Q1 2023 May 11, 2023	SELL	$27.71 - $40.93 $15,905 - $23,493	-574 Reduced 7.36%	7,230 $212,000
Q4 2022 Feb 13, 2023	BUY	$29.75 - $39.26 $222,173 - $293,193	7,468 Added 2222.62%	7,804 $288,000
Q3 2022 Nov 10, 2022	SELL	$17.15 - $30.92 $2.09 Million - $3.78 Million	-122,107 Reduced 99.73%	336 $9,000
Q2 2022 Aug 12, 2022	BUY	$6.85 - $19.93 $235,078 - $683,957	34,318 Added 38.94%	122,443 $2.36 Million
Q1 2022 May 13, 2022	BUY	$12.85 - $32.9 $1.13 Million - $2.9 Million	88,125 New	88,125 $1.13 Million

Others Institutions Holding AMLX

# of Institutions

139

Shares Held

46.5M

Call Options Held

226K

Put Options Held

909K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $330M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account